REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today
that a research team in Washington, D.C. has found that
dystrophin-deficient Mdx mice, treated twice a week for six months with
Tβ4, showed a significant increase in skeletal muscle regenerating
fibers compared to untreated mice. No effects related to muscle function
or fibrosis and no adverse reactions were observed in the mice. Mdx mice
are used as models for Duchenne muscular dystrophy to evaluate potential
therapeutic compounds. According to the research team, “In exercised
dystrophin deficient mice, chronic administration of Tβ4 increased the
number of regenerating fibers in skeletal muscle and could have a
potential role in the treatment of skeletal muscle disease in Duchenne
muscular dystrophy.” Because Tβ4 stimulates cell migration and
anti-apoptosis pathways in skeletal muscle cultures, these data further
suggest a role for Tβ4 in muscle degenerative diseases and injury.
“This study is particularly important as it provides the first direct
correlation of gene expression data with in vivo administration
and histological localization of Tβ4 in muscle tissue”
“This study is particularly important as it provides the first direct
correlation of gene expression data with in vivo administration
and histological localization of Tβ4 in muscle tissue,” stated Dr. Allan
L. Goldstein, Professor of Biochemistry and Molecular Biology at the
George Washington University Medical Center, Washington, DC, and
RegeneRx’s chief scientific advisor.
Creatine in your diet may benefit your digestive system